Zusammenfassung
Die Therapie pulmonaler Manifestationen bei Autoimmunerkrankungen hängt neben der
Art und Schwere der Lungenmanifestation von der zu Grunde liegenden Erkrankung ab.
Im vorliegenden Übersichtsartikel werden die Therapieprinzipien bei Vaskulitiden,
rheumatischen Erkrankungen und Kollagenosen beschrieben.
Summary
Pulmonary manifestations of autoimmune diseases are treated depending on the involved
lung structure and the underlying disorder. In this review the therapeutic approach
in the case of vascultitis, rheumatoid arthritis and connective tissue disease will
be presented.
Schlüsselwörter
Alveolitis - Diffuse alveoläre Hämorrhagie - Fibrose - Kollagenose - Pulmonale Hypertonie
- Vaskulitis
Key words
alveolitis - connective tissue disease - diffuse alveolar haemorrhage - fibrosis -
pulmonary hypertension - vasculitis
Literatur
- 1
Cherin P, Brenot F, Bletry O. et al .
Pulmonary hypertension in SLE: Hemodynamic effects of vasodilating agents.
Lupus.
1995;
4
171S-176S
- 2
De Groot K, Rasmussen N, Bacon P A. et al .
Randomized trial of cylcophosphamid versus methotrexat for induction of remission
in early systemic antineutrophil cytoplasmatic antibody-associated vasculitis.
Arthritis Rheum.
2005;
52
2461-2469
- 3
De Remee R A.
WegenerŽs granulomatosis.
Ann Intern Med.
1992;
117
619-620
- 4
Fauci A S, Haynes B F, Katz P, Wolff S M.
WegenerŽs granulomatosis: prospective clinical and therapeutic experience with 85
patients for 21 years.
Ann Intern Med.
1983;
98
76-85
- 5
Hoyles R K, Ellis R W, Wellsbury J. et al .
A multicenter, prospective, randomized, double-blind, placebo-controlled trial of
corticosteroids and intravenous cylcophosphamide followed by oral azathioprine for
the treatment of pulmonary fibrosis in scleroderma.
Arthritis Rheum.
2006;
54
3962-3970
- 6
Hunninghake G W, Fauci A S.
Pulmonary involvement in the collagen vascular disease.
Am Rev Respir Dis.
1979;
119
471-503
- 7
Jayne D.
Evidence-based treatment of systemic vasculitis.
Rheumatology (Oxford).
2000;
39
585-595
- 8
Jayne D, Rasmussen N, Andrassy K. et al .
A randomized trail of maintance therapy for vasculitis associated with antineutrophil
antibody-associated vasculitis.
N Engl J Med.
2003;
349
36-44
- 9
Klemmer P J, Chalermskulrat W, Reif M S. et al .
Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel
vasculitis.
Am J Kidney Dis.
2003;
42
1149-1153
- 10
Matthay R A, Schwartz M I, Petty T L. et al .
Pulmonary manifestations of systemic lupus erythematosus. Review of twelve cases of
acute lupus pneumonitis.
Medicine.
1975;
54
397-409
- 11
Rihova Z, Jancova E, Merta M. et al .
Daily oral versus pulse intravenous Cyclophosphamide in the therapy of ANCA-associated
vasculitis: preliminary single center experience.
Prague Med Rep.
2004;
105
64-68
- 12
Rubin L J, Badesch D B, Barst R J. et al .
Bosentan therapy for pulmonary arterial hypertension.
N Engl J Med.
2002;
346
896-903
- 13
Schwarz M I, Matthay R A, Sahn S A. et al .
Interstitial lung disease in polymyositis und dermatomyositis: Analysis of six cases
and review of the literature.
Medicine.
1979;
55
89-104
- 14
Sullivan W D, Hurst D J, Harmon C E. et al .
A prospective evaluation emphazising pulmonary involvement in patients with mixed
connective tissue disease.
Medicine.
1984;
63
92-107
- 15
Tashkin D P, Elashoff R, Clements P J. et al .
Cylcophosphamide versus placebo in scleroderma lung disease.
N Engl J Med.
2006;
354
2655-2666
Prof. Dr. med. Peter Zabel
Medizinische Klinik, Forschungszentrum Borstel
Parkallee 35
23845 Borstel
Telefon: 04537/188301
Fax: 04537/188313
eMail: pzabel@fz-borstel.de
